Eczema Trial, Recruiting NCT06884163 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Eczema
Back to Eczema

Eczema Trial, Recruiting

NCT06884163
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old and have been diagnosed with long-term eczema on your hands, whether caused by internal factors (like skin sensitivity) or external triggers (like contact with certain substances)
  • Your hand eczema has been present for at least 3 months, or you have had 2 or more flare-ups in the past year
  • You have atopic dermatitis (a type of eczema) affecting your hands and other parts of your body, as long as less than 30% of your total body surface is affected by eczema lesions

Who may not be able to join:

  • You are currently using or have previously used medications that suppress the immune system, or biological treatments (injections or infusions that target specific parts of the immune system), which could affect your hand eczema — short courses of steroid tablets lasting less than one month may be an exception (confirm with trial site)
  • You have taken steroid tablets or similar medications within the last month before joining the study
  • You have used steroid creams, ointments, or similar skin treatments (including calcineurin inhibitor creams) within one week before joining the study
  • Your hand eczema is caused by a combination of different triggers (for example, both allergic reactions and atopic skin), or your eczema cause cannot be clearly identified — these cases would be excluded from the study's data analysis (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ketty Peris, Prof, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phone: +390630155284

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 January 2025
Est. completion
1 January 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

spatial proteomics analysis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov